Shenzhen Hepalink to acquire Scientific Protein Labs for US $337.5 mn
Shenzhen Hepalink Pharmaceutical Co., Ltd, one of the world’s largest suppliers of processed heparin, announced that it has entered into a stock purchase agreement to acquire Scientific Protein Laboratories, LLC. (SPL), a leading global, independent manufacturer and supplier of active pharmaceutical ingredients . With the acquisition, Hepalink will expand its presence as one of the leading suppliers of heparin worldwide, while providing the combined company with greater product development and growth opportunities in new markets for its full line of APIs, including pancreatic enzyme and heparin products. This acquisition allows for greater investment in R&D, new products and processes, and will form a stronger company with enhanced cutting-edge R&D capabilities in the global heparin API sector.
Under the terms of the agreement, Hepalink has agreed to acquire Scientific Protein Laboratories for US$ 337.5 million in cash plus certain contingent payments.
“This represents an exciting opportunity for both companies and all of their employees in an increasingly global industry,” said Li Li, chairman and chief executive officer of Hepalink. “After the acquisition, Hepalink will be able to further enhance the stability and safety of the supply of the heparin product raw materials, strengthen Hepalink’s globally leading advantages in technology, processing techniques, quality and safety standards, and form a global heparin API manufacturing, R&D and distribution network for Hepalink. The transaction will open new markets for API products and allow for greater investment in R&D, new products and processes. Operating at the high level of US and international safety standards, the combined company will continue its absolute commitment to global best practices in product safety and quality as a trusted supplier of ingredients for critical medicines.”
“We are excited about this transaction and what it means for Scientific Protein Laboratories,” said Robert Mills, chief executive officer of SPL. “This will expand our ability to develop and grow both our domestic and international businesses and to continue to conduct cutting-edge research on new products. We do not anticipate any changes in how we currently do business. We will become part of a very successful company that shares our commitment to safety and quality.”